Shares of Celsion Corporation CLSN surged over 13 percent Friday following an announcement by the company on its GEN-1, a DNA-based immunotherapy, as a single agent in advanced platinum-resistant and recurrent ovarian cancer patients.
According to the company’s press release, clinical and preclinical data has provided support for advancing GEN-1 into clinical development in the front-line setting.
The company also announced that the U.S. FDA has accepted, without comment, its planned Phase 1 dose-escalation clinical trial of GEN-1 in combination with the standard of care in neo-adjuvant ovarian cancer, which is expected to commence in mid-2015 at five to six U.S. clinical centers.
Khursheed Anwer, Ph.D., Executive Vice President and Chief Scientific Officer of Celsion stated:
"These important findings significantly strengthen our established clinical and preclinical data providing additional evidence of GEN-1's ability to effectively recruit a cellular immune system response, widely known for its anti-cancer activity. Evidence now in platinum-resistant and recurrent ovarian cancer patients, populations which historically have had little to no response to new investigational therapies, is highly encouraging.”
Anwer also commented that based on “the level of activity observed in these advanced patient populations, we believe that GEN-1 has the potential to produce a robust response in the neo-adjuvant setting, where patients typically have healthier immune systems and no prior treatment with immunosuppressive drugs.”
Celsion Corporation recently traded at $3.11, up 11.47 percent.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
